Strides Pharma Science Ltd. Financials: Quarterly Results
Revenue
1301.51
Cr.
PAT
208.15
Cr.
EBITDA
292.18
Cr.
Strides Pharma Science Ltd. Q3FY26 Financial Metrics
| Indicator | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 1194.65 | 1220.83 | 1119.74 | 1190.39 | 1153.67 |
| Total Income From Operations (Cr.) | 1194.65 | 1220.83 | 1119.74 | 1190.39 | 1153.67 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 292.18 | 209.06 | 177.77 | 180.99 | 167.50 |
| P/L Before Exceptional Items & Tax (Cr.) | 248.81 | 162.94 | 130.31 | 130.67 | 115.32 |
| P/L After Tax from Ordinary Activities (Cr.) | 208.15 | 132.57 | 105.49 | 82.49 | 89.09 |
| Net Profit/Loss For the Period (Cr.) | 208.15 | 132.57 | 105.49 | 82.49 | 89.09 |
| Basic EPS | 21.93 | 13.84 | 10.81 | 8.92 | 9.56 |
FAQs
Strides Pharma Science Ltd. announced its quarterly results for Q3 FY2026 on January 30, 2026.
In Q3 FY2026, Strides Pharma Science Ltd. are as follows:
Revenue: ₹1301.51 crore
Net Profit: ₹208.15 crore.
For Q3 FY2026, Strides Pharma Science Ltd. posted ₹1301.51 crore in revenue and ₹208.15 crore in net profit.
Past quarterly results for Strides Pharma Science Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.